FDA Clears Two Ultrasound Systems From Esaote

Esaote has secured U.S. Food and Drug Administration (FDA) approval for its MyLab A50 and MyLab A70 ultrasound systems. The products had previously been unveiled to the international medical community.

MyLab A50 and MyLab A70 ultrasound systems are engineered to deliver exceptional flexibility and performance across a wide range of clinical environments, according to the company. These new models are designed to be highly portable, featuring compact sizes and battery operation to meet the mobility needs of healthcare practitioners.

“The new A-series emphasizes user experience with a diverse range of interface options, including both a conventional and touch control panel,” stated Thomas Will, ultrasound sales director at Esaote North America. “The devices boast an intuitive, easy-to-clean design that allows clinicians to operate efficiently and confidently.”

The MyLab A50 and MyLab A70 are equipped to handle various clinical applications, from routine diagnostics to advanced imaging techniques. They support the latest ultrasound functionalities, such as liver elastography and attenuation imaging, along with comprehensive cardiology tools like strain analysis, enabling detailed and multiparametric assessments.

Harnessing artificial intelligence and cutting-edge imaging advancements, these systems empower healthcare providers to make precise, informed diagnoses with greater confidence. Marking a significant milestone for Esaote’s renewed brand mission, the MyLab A50 and MyLab A70 introduction underscores the company’s dedication to improving patient outcomes.

Esaote manufacturers medical diagnostic systems. The firm considers itself a leader in dedicated magnetic resonance imaging and one of the main players in healthcare information technology. Ultrasound is its core business, and since 2002 it has been active in the interventional sector.